Treatment of depression with cognitive impairment

Medvedev V.E.

Department of Psychiatry, Psychotherapy and Psychosomatic Pathology of the Peoples' Friendship University of Russia

SPIN RSCI: 2814-4975
Scopus AuthorID: 55545252400
ResearcherID: AAH-1849-2020
ORCID: 0000-0001-8653-596X

Ter-israelyan A.Yu.

Russian Peoples Friendship University, Moscow;
City Psychiatric Hospital №13, №71, Moscow

Frolova V.I.

Kafedra psikhiatrii, psikhoterapii i psikhosomaticheskoĭ patologii fakul'teta povysheniia kvalifikatsii meditsinskikh rabotnikov Rossiĭskogo universiteta druzhby narodov

Korovyakova E.A.

Psychiatric Hospital №13, Moscow, Russia

Gushanskaya E.V.

Russian Peoples Friendship University, Moscow;
City Psychiatric Hospital №13, №71, Moscow

Treatment of depression with cognitive impairment

Authors:

Medvedev V.E., Ter-israelyan A.Yu., Frolova V.I., Korovyakova E.A., Gushanskaya E.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(2): 77‑80

DOI: 10.17116/jnevro20181182177-80

Downloaded: 207

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Medvedev VE, Ter-israelyan AYu, Frolova VI, Korovyakova EA, Gushanskaya EV. Treatment of depression with cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(2):77‑80. (In Russ.)
https://doi.org/10.17116/jnevro20181182177-80

Close metadata

Recommended articles:

A perspective on the application of CRISPR/CAS9 genome editing system to study of molecular-genetic basis of mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):27-33

Identifying the neurostimulation target for treatment of cognitive impairment in aging and early cerebral small vessel disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):34-41

Asthenic disorders correction with Recognan. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):57-62

Associations between components of metabolic syndrome and cognitive impairment in patients with schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):82-87

Validation of screening method based on EEG analysis for the risk assessment of psychiatric and behavioral disorders: a pilot study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):88-96

A clinical case of the new-onset bipolar affective disorder in the postcovid period. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):125-129

Pathogenetic basis of modern approaches to the therapy of sleep disorders in the clinic of depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):69-74

Features of the clinical picture of affective disorders in women during the menopausal transition and early postmenopause. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):75-79

Prevalence of cognitive impairment in older adults in the Russian Federation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):5-11

Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):17-24

Objective. To investigate the efficacy and tolerability of monotherapy with agomelatine (valdoxan) in depressive patients with marked cognitive impairment. Material and methods. Thirty-five patients (women 77.1%) were recruited to participate in the study. Mean age of patients was 48.9±3.5 years. The following scales and cognitive tests were used: HAM-21, CGI, HADS, MMSE, the Stroop task, the Rey test, RAVLT. Effective therapeutic doses of valdoxan were 25mg per day in 77.1% of patients, 50 mg per day beginning from week 2 in 22.9%. Cognitive impairment was found in astheno-apathic depression (51.4%), anxiety-hypochondriacal depression (28.6%), anhedonic depression (5.7%). Results. The results showed that 74.3% of patients were responders and 51.4% were in remission. The dynamic of cognitive impairment demonstrated the positive effect of treatment with agomelatine (valdoxan). Beneficial safety profile of valdoxan was confirmed. Conclusion. Valdoxan is the effective and relatively safe antidepressant; it can be recommended for treatment of depression with cognitive impairment in therapeutic doses for at least 6 weeks.

Keywords:

depression

cognitive impairment

agomelatine

Authors:

Medvedev V.E.

Department of Psychiatry, Psychotherapy and Psychosomatic Pathology of the Peoples' Friendship University of Russia

SPIN RSCI: 2814-4975
Scopus AuthorID: 55545252400
ResearcherID: AAH-1849-2020
ORCID: 0000-0001-8653-596X

Ter-israelyan A.Yu.

Russian Peoples Friendship University, Moscow;
City Psychiatric Hospital №13, №71, Moscow

Frolova V.I.

Kafedra psikhiatrii, psikhoterapii i psikhosomaticheskoĭ patologii fakul'teta povysheniia kvalifikatsii meditsinskikh rabotnikov Rossiĭskogo universiteta druzhby narodov

Korovyakova E.A.

Psychiatric Hospital №13, Moscow, Russia

Gushanskaya E.V.

Russian Peoples Friendship University, Moscow;
City Psychiatric Hospital №13, №71, Moscow

List of references:

Shmukler AB. Cognitive impairment in depressive syndrom. Sotsial’naya i klinicheskaya psikhiatriya. 2016;26:1:72-76. (In Russ.)
Airaksinen E, Wahlin A, Forsell Y, Larsson M. Low episodic memory performance as a premorbid marker of depression: evidence from a 3-year follow-up. Acta Psychiatr Scand. 2007;115:458-465. https://doi.org/10.1111/j.1600-0447.2006.00932.x
Lee RSC, Hermens DF, Porter MA, Redoblado-Hodge MA. A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. J Affect Disord. 2012;140:113-124. https://doi.org/10.1016/j.jad.2011.10.023
Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011;41:6:1165-1174. https://doi.org/10.1017/s0033291710001911
Papakostas GI, Culpepper L. Understanding and managing cognition in depressed patient. J Clin Psychiatry. 2015;76:4:419-425. https://doi.org/10.4088/jcp.13086ah1c
Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44:2029-2040. https://doi.org/10.1017/s0033291713002535
Medvedev VE, Retiunsky KYu, Ovchinnikov AA, Barylnik YuB, Shmilovich AA, Antokhin EYu, Usov GM, Cheremin RA, Poletsky VM, Onegin AV, Kireeva IP, Frolova VI, Filippova NV, Antonova AA, Deeva MA, Onegina D.A. The differences in the estimation of depression severity by psychiatrists and patients during the combined treatment with agomelatine (a multicenter study «EMOTSIA»). Zh Nevrol Psikhiatr im. S.S. Korsakova. 2016;116: 11:26-34. (In Russ.) https://doi.org/10.17116/jnevro201611611126-34
Medvedev VE. Treatment of mild to moderate Major Depressive Disorder with Agomelatine in patients with cardiovascular disorders (National Observational Multicenter Study «PULSE»). European Psychiatry (Abstracts of the 24th European Congress of Psychiatry). 2016;33:516. https://doi.org/10.1016/j.eurpsy.2016.01.1508
Medvedev VE. Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disorders: results of the National Multicenter Observational Study PULSE. Neuropsychiatric disease and treatment. 2017;13:1141-1151. https://doi.org/10.2147/NDT.S129793
Pehrson AL, Leiser SC, Gulinello M, Dale E, Li Y, Waller JA, Sanchez C. Treatment of cognitive dysfunction in major depressive disorder — a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin — norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. Eur J Pharmacol. 2015;753:19-31. https://doi.org/10.1016/j.ejphar.2014.07.044
Audinot V, Mailliet F, Lahaye-Brasseur C, Bonnaud A, Le Gall A, Amossé Ch, Dromaint S, Rodriguez M, Nagel N, Galizzi J-P, Malpaux B, Guillaumet G, Lesieur D, Lefoulon F, Renard P, Delagrange Ph, Boutin JA. New selective ligands of human cloned melatonin MTI and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003;367:553-561. https://doi.org/10.1007/s00210-003-0751-2
Loo H, Hale A, D’haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002;17:239-247. https://doi.org/10.1097/00004850-200209000-00004
Millan MJ, Gobert A, Lejeune F. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydro-xytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306:954-964. https://doi.org/10.1124/jpet.103.051797
Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007;10:661-673. https://doi.org/10.1017/s1461145707007766
Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007;62:1217-1227. https://doi.org/10.1016/j.biopsych.2007.03.027
Stahl SM. Essential psychopharmacology. Cambridge Medicine. 2013;608.
Makhortova IS, Shiriaev OYu, Tsygankov BD. Comparative analysis of cognitive characteristics and BMI dynamics in patients with depression and eating disorders. Psychiatry and Psychopharmacotherapy. 2016;18(4):28-31. (In Russ.)
Medvedev VE. Perspektivy ispol’zovaniya melatoninergicheskikh preparatov v terapii depressii u patsientov s serdechno-sosudistymi zabolevaniyami. Psychiatry and Psychopharmacotherapy. 2010;3:19-23. (In Russ.)
Medvedev VE. Terapiya nepsikhoticheskikh depressii v ramkakh involyutsionnoi isterii (opyt primeneniya Valdoksana). Psychiatry and Psychopharmacotherapy. 2011;4:14-18. (In Russ.)
Medvedev VE. Dysphoric Depression Monotherapy with Valdoxan. Psychiatry and Psychopharmacotherapy. 2016;18(1):20-23. (In Russ.)
Medvedev VE. Valdoxan (agomelatine) in combined therapy of moderate and severe non-psychotic depressions. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2012;112(5):37-40. (In Russ.)
Chernova EV, Kozhechkina OV, Ter-Israelyan AYu, Medvedev VE. Agomelatine (valdoxan) in treatment of endogenous depression in day patient department. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2016;116:10:43-46. (In Russ.) https://doi.org/10.17116/jnevro201611610143-46
Medvedev VE. Use of Valdoxan (Agomelatin) in the Combined Treatment of Moderate and Severe Nonpsychotic Depression. Neuroscience and Behavioral Physiology. 2013;7(43):878-882. https://doi.org/10.1007/s11055-013-9822-0

Close metadata